Los Angeles, CA – As Parkinson’s disease diagnoses continue to rise in the U.S., limited patient access to movement disorder specialists means the job of delivering the often-devastating, lifechanging news falls on primary care physicians or community neurologists who may not have the necessary expertise for this sensitive task. A...
Latest News
TOKUSHIMA, Japan — As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a Phase II clinical trial, has demonstrated fascinating longer median progression-free survival...
SOUTH SAN FRANCISCO, Calif. — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its BBB-crossing enzyme replacement...
SOUTH SAN FRANCISCO, Calif. — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme...
PLAINSBORO, N.J. and BAGSVÆRD, Denmark — Today, the New England Journal of Medicine (NEJM) published 26-week results from the phase 3 FRONTIER2 trial evaluating the efficacy and safety of once-monthly and once-weekly denecimig (Mim8) in adults and adolescents 12 years of age and older with hemophilia A (congenital Factor VIII (FVIII) deficiency),...
DAKAR, Senegal — World-famous singer Youssou Ndour has a voice that is recognized across the globe. Now he’s using that voice to amplify the fight against malaria in his home country of Senegal with a new song “Xeex Sibbiru” (“Fight Malaria” in Wolof) and a multi-year partnership with Malaria No...
ST. PAUL, Minn. – People with memory problems who are depressed are more likely to develop Alzheimer’s disease compared to people who are not depressed, according to a study published in the June 16, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. However, the...
MINNEAPOLIS – In some diseases, the underlying processes can start years before a diagnosis is made. A new study finds that people who later develop multiple sclerosis (MS) are more likely to have conditions like depression, constipation and urinary tract infections five years before their MS diagnosis than people who...
TAMPA, Fla. — Pancreatic cancer presents a challenging prognosis, marked by a five-year overall survival rate of merely 12.5%. Diagnosis frequently occurs at an advanced stage, characterized by metastasis to distant sites. The intricate molecular mechanisms governing pancreatic cancer metastasis remain a subject of ongoing research and exploration. In a recent...
SAN DIEGO, CA – Dermata Therapeutics, Inc., a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled “Compositions for the treatment of skin conditions,” (Japanese...